Business Context and Reporting Period
This Form 8-K, dated September 14, 2021, reports the consummation of the initial public offering (IPO) by First Light Acquisition Group, Inc. (the "Company"). The filing details the sale of units and private placement warrants, marking the Company's entry into public markets. Note: While the request metadata mentions Calidi Biotherapeutics, Inc., the provided filing text explicitly concerns First Light Acquisition Group, Inc.
Key Financial Metrics
- Gross Proceeds from IPO: $230,000,000 from the sale of 23,000,000 units at $10.00 per unit.
- Gross Proceeds from Private Placement: Approximately $5,095,733 from the sale of 3,397,155 warrants at $1.50 per warrant.
- Total Funds in Trust Account: $230,000,000, consisting of $227,664,942 from IPO proceeds (including deferred underwriting discounts) and $2,335,058 from private placement proceeds.
- Deferred Underwriting Discounts: Approximately $8,050,000.
- Warrant Exercise Price: $11.50 per share.
Material Changes
The primary material change is the transition from a private entity to a publicly traded company on the New York Stock Exchange. The Company issued 23,000,000 units, including 3,000,000 units from the underwriter's exercise of its over-allotment option. Concurrently, the Company secured additional capital through a private placement to its sponsor and an affiliate.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, risk factors, or management commentary beyond the factual description of the transaction. The proceeds are held in a trust account maintained by Continental Stock Transfer & Trust Company, which is standard for Special Purpose Acquisition Companies (SPACs) pending a business combination. An audited balance sheet as of September 14, 2021, is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact composition of the trust account and the terms governing the release of funds.
- Review the audited balance sheet (Exhibit 99.1) for a complete picture of assets and liabilities post-IPO.
- Confirm the identity of the underwriters and the specific terms of the deferred underwriting discounts.
- Examine the rights and redemption terms associated with the Class A common stock and warrants.
- Check for any subsequent filings regarding the identification of a target business for acquisition.